Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke

Trial Profile

Phase 1 trial of ACT-017 for the treatment of Acute Ischemic Stroke

Planning
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs ACT 017 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 19 May 2017 According to an Acticor Biotech media release, the company is planning to initiate this trial in October 2017 and to end in January 2018.
    • 09 Feb 2017 New trial record
    • 07 Feb 2017 According to an Acticor Biotech media release, company should start its Phase I 6 months earlier than originally planned because of encouraging pre-clinical results and positive regulatory meetings.The first subject could thus be scheduled for early Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top